14th Dec 2021 21:18
Arecor Therapeutics PLC - Cambridge-based biotechnology company - Signs exclusive formulation study partnership with unnamed technology firm.
Under the deal, Arecor will use its formulation platform Arestat to develop a stable and liquid formulation. The partner will fund the development work and will keep an option to acquire the rights to the new formulation under a technology licensing model.
"We continue to expand the multiple potential applications of our innovative Arestat platform. Supporting our partner's molecular testing platform augments our portfolio, showcasing the breadth of our technology platform's potential. Our partner's products are used for applications in life sciences, oncology, reproductive health, agriculture and other emerging segments, expanding our reach into new markets," says Chief Executive Officer Sarah Howell.
Current stock price: 420.00 pence, up 9.1% on Tuesday
Year-to-date change: up 73% since June 4
By Dayo Laniyan; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Arecor Therape